<DOC>
	<DOCNO>NCT01468077</DOCNO>
	<brief_summary>This multi-center , randomize , parallel-group , active-controlled , open-label study evaluate safety efficacy shorten RoActemra/Actemra ( tocilizumab ) infusion time compare normal infusion time . Patients randomize 8 mg/kg RoActemra/Actemra infusion 31 minute every 4 week RoActemra/Actemra 8 mg/kg infusion 60 minute every 4 week . The anticipated time study treatment 24 week .</brief_summary>
	<brief_title>A Study Patients With Moderate Severe Active Rheumatoid Arthritis Comparing Different Infusion Durations RoActemra/Actemra ( Tocilizumab ) Treatment</brief_title>
	<detailed_description />
	<mesh_term>Arthritis</mesh_term>
	<mesh_term>Arthritis , Rheumatoid</mesh_term>
	<criteria>Adult patient , least 18 year age , inclusive Diagnosis rheumatoid arthritis least 6 month duration Moderate severe active rheumatoid arthritis ( DAS28 &gt; /=3.2 ) Patients receive least 1 diseasemodifying antirheumatic drug ( DMARD ) and/or 1 TNFalfainhibitors period least 8 week Major surgery ( include joint surgery ) within 8 week prior screen plan surgery within 6 month follow randomization Rheumatic autoimmune disease rheumatoid arthritis Prior history current inflammatory joint disease rheumatoid arthritis Functional class IV ( ACR criterion ) History severe allergic reaction human , humanize murine monoclonal antibody Known active current history recurrent infection ( include tuberculosis ) Primary secondary immunodeficiency ( history currently active ) Body weight &gt; 150 kg Previous treatment celldepleting therapy Previous treatment tocilizumab</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2015</verification_date>
</DOC>